Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Inclusion Criteria:

* 18 years of age or older
* Endometrial cancer
* Patients must have been treated with at least one line of chemotherapy, but not more than two lines of chemotherapy, and experienced progressive disease
* At least one measurable lesion
* ECOG performance status less than or equal to 1
* Minimum life expectancy of 3 months
* Adequate renal and hepatic function
* Adequate bone marrow function
* Serum cholesterol \<350 mg/dL and triglycerides \< 400 mg/dL
* Able to understand and give written informed consent
* Females of childbearing potential must have a negative pregnancy test and use approved contraception from screening to 30 days after the last study drug is given

Exclusion Criteria:

* Two lines of chemotherapy for recurrent or metastatic disease
* Chemotherapy for recurrent or metastatic disease administered within six months of adjuvant therapy
* More than two lines of chemotherapy of any type
* Prior therapy with hormonal agents
* Women who are pregnant or lactating
* Presence of brain or other central nervous system metastases
* Prior therapy with rapamycin, rapamycin analogues or tacrolimus or known sensitivity to these agents
* Anticancer treatment (chemotherapy, radiotherapy) within 4 weeks prior to randomization
* Ongoing toxicity associated with prior anticancer therapy
* Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to randomization.
* Another primary malignancy within the past five years (except for non-melanoma skin cancer and cervical carcinoma in situ)
* Known Grade 3 or 4 hypersensitivity to macrolide antibiotics
* Significant uncontrolled cardiovascular disease
* Active infection
* Known HIV infection
* Known Hepatitis B or C infection
* Newly diagnosed (within 3 months before enrollment) or poorly controlled Type 1 or 2 diabetes
* Concurrent treatment with immunosuppressive agents
* A requirement for concurrent treatment with medication that strongly induce or inhibit cytochrome P450 (CYP3A)